Redhill Biopharma Ltd. (RDHL) News
Filter RDHL News Items
RDHL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest RDHL News From Around the Web
Below are the latest news stories about REDHILL BIOPHARMA LTD that investors may wish to consider to help them evaluate RDHL as an investment opportunity.
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced DevelopmentRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced positive results from new in vivo studies of opaganib[1] as a treatment for gastrointestinal acute radiation syndrome (GI-ARS), undertaken as part of the U.S. government's Radiation and Nuclear Countermeasures Program (RNCP) product pipeline development contract awarded to opaganib, that further confirm opaganib's protective activity in models of GI-ARS. |
RedHill Biopharma awarded judgement of approx $8M by NY Supreme CourtRedHill Biopharma (RDHL) announced that the Company has been awarded approximately $8 million, plus costs in a summary judgment by the Supreme Court of the State of New York, New York County, in its legal proceedings against Kukbo Co. Ltd., domiciled in South Korea. The case refers to Kukbo’s failure to make agreed payments to RedHill, pursuant to a Subscription Agreement, dated October 25, 2021, and a subsequent Exclusive License Agreement, dated March 14, 2022, entered into by the two companie |
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme CourtRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the Company has been awarded approximately $8 million (consisting of $6.5 million plus interest amounting to approximately $1.5 million), plus costs in a summary judgment by the Supreme Court of the State of New York, New York County (the "Court"), in its legal proceedings (Index number: 653200/2022) against Kukbo Co. Ltd. ("Kukbo"), domiciled in South Korea. |
RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRNDRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the Company has been selected to further elaborate on opaganib's[1] potential in a presentation to U.S. government representatives at the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense's (JPEO-CBRND) "Host Directed Therapeutics Industry Day". The meeting is scheduled to take place October 29-30, 2024, at the United States Paten |
RedHill Biopharma and Duke Collaborate on Opaganib DevelopmentRedHill Biopharma (RDHL) has released an update. RedHill Biopharma has announced a collaboration with Duke University School of Medicine to test the drug opaganib as a treatment for phosgene inhalation injury, a potential public safety threat. The partnership aims to advance opaganib development under FDA guidelines, addressing the lack of approved antidotes for this toxic industrial chemical. Opaganib’s broad potential applications and its ongoing evaluation by U.S. government programs highligh |
RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation InjuryRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the signing of a collaborative research agreement with Duke University School of Medicine outlining plans for multiple in vivo studies. The program is designed to test opaganib[2] as a potential medical countermeasure to treat phosgene inhalation injury, aimed at providing results sufficient to advance opaganib into further definitive U.S. government-sponsored development un |
RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola TreatmentRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. government's Biomedical Advanced Research and Development Authority (BARDA), a center of the Department of Health and Human Services (HHS)' Administration for Strategic Preparedness and Response (ASPR), has selected opaganib2 for development to treat exposure to Ebola virus disease (EBOV). |
RedHill Biopharma Secures Opaganib COVID-19 PatentRedHill Biopharma (RDHL) has released an update. RedHill Biopharma Ltd. has announced a new U.S. patent for Opaganib, targeting the treatment of COVID-19, with validity extending through 2041. The patent covers the identification of a novel biomarker predictive of the drug’s effectiveness and follows published data indicating significant patient improvements, including oxygenation, reduced intubation needs, and mortality rates. Opaganib is a first-in-class, orally administered drug with potentia |
RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million CaliforniansRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the renewal of its contract with Medi-Cal, California's Medicaid healthcare program, to maintain Talicia's first-line position on the Medi-Cal Fee-For-Service (FFS) Contract Drug List (CDL) with no prior authorization and a $0 copay, effective October 1, 2024. |
RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new U.S. patent for identification of a novel biomarker of coronavirus pneumonia (≤60% fraction of inspired oxygen (FiO2)) prognostic for potential opaganib[2] efficacy in treating COVID-19, valid through 2041 (U.S. Patent and Trademark Office Number: 12,115,150, date of grant to be: October 15, 2024). |